vs

Side-by-side financial comparison of Proto Labs Inc (PRLB) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

Proto Labs Inc is the larger business by last-quarter revenue ($139.3M vs $69.8M, roughly 2.0× RIGEL PHARMACEUTICALS INC). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs 5.8%, a 378.2% gap on every dollar of revenue. On growth, RIGEL PHARMACEUTICALS INC posted the faster year-over-year revenue change (21.2% vs 10.4%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 5.3%).

Protolabs is a company that provides rapid manufacturing of 3D printed, CNC-machined, sheet metal, and injection-molded custom parts for prototyping and production. Markets like medical devices, aerospace, electronics, appliances, automotive and consumer products use these parts. Protolabs' headquarters are located in Maple Plain, Minnesota, with Minnesota-based manufacturing facilities in Plymouth, Brooklyn Park, and Rosemount, along with additional facilities in Nashua, New Hampshire and Ca...

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

PRLB vs RIGL — Head-to-Head

Bigger by revenue
PRLB
PRLB
2.0× larger
PRLB
$139.3M
$69.8M
RIGL
Growing faster (revenue YoY)
RIGL
RIGL
+10.8% gap
RIGL
21.2%
10.4%
PRLB
Higher net margin
RIGL
RIGL
378.2% more per $
RIGL
384.0%
5.8%
PRLB
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
5.3%
PRLB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
PRLB
PRLB
RIGL
RIGL
Revenue
$139.3M
$69.8M
Net Profit
$8.1M
$268.1M
Gross Margin
45.6%
91.5%
Operating Margin
7.1%
33.2%
Net Margin
5.8%
384.0%
Revenue YoY
10.4%
21.2%
Net Profit YoY
125.4%
1769.2%
EPS (diluted)
$0.29
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRLB
PRLB
RIGL
RIGL
Q1 26
$139.3M
Q4 25
$136.5M
$69.8M
Q3 25
$135.4M
$69.5M
Q2 25
$135.1M
$101.7M
Q1 25
$126.2M
$53.3M
Q4 24
$121.8M
$57.6M
Q3 24
$125.6M
$55.3M
Q2 24
$125.6M
$36.8M
Net Profit
PRLB
PRLB
RIGL
RIGL
Q1 26
$8.1M
Q4 25
$268.1M
Q3 25
$7.2M
$27.9M
Q2 25
$4.4M
$59.6M
Q1 25
$3.6M
$11.4M
Q4 24
$14.3M
Q3 24
$7.2M
$12.4M
Q2 24
$4.5M
$-1.0M
Gross Margin
PRLB
PRLB
RIGL
RIGL
Q1 26
45.6%
Q4 25
44.2%
91.5%
Q3 25
45.3%
93.2%
Q2 25
44.3%
95.6%
Q1 25
44.1%
91.7%
Q4 24
42.7%
89.9%
Q3 24
45.6%
85.5%
Q2 24
45.0%
92.4%
Operating Margin
PRLB
PRLB
RIGL
RIGL
Q1 26
7.1%
Q4 25
5.0%
33.2%
Q3 25
6.5%
40.9%
Q2 25
3.7%
60.1%
Q1 25
3.6%
23.9%
Q4 24
-1.2%
28.9%
Q3 24
6.8%
25.4%
Q2 24
4.8%
1.2%
Net Margin
PRLB
PRLB
RIGL
RIGL
Q1 26
5.8%
Q4 25
384.0%
Q3 25
5.3%
40.2%
Q2 25
3.3%
58.6%
Q1 25
2.9%
21.5%
Q4 24
24.9%
Q3 24
5.7%
22.5%
Q2 24
3.6%
-2.8%
EPS (diluted)
PRLB
PRLB
RIGL
RIGL
Q1 26
$0.29
Q4 25
$0.25
$14.11
Q3 25
$0.30
$1.46
Q2 25
$0.18
$3.28
Q1 25
$0.15
$0.63
Q4 24
$-0.01
$0.82
Q3 24
$0.29
$0.70
Q2 24
$0.18
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRLB
PRLB
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$124.0M
$155.0M
Total DebtLower is stronger
$52.5M
Stockholders' EquityBook value
$683.1M
$391.5M
Total Assets
$778.6M
$513.6M
Debt / EquityLower = less leverage
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRLB
PRLB
RIGL
RIGL
Q1 26
$124.0M
Q4 25
$128.1M
$155.0M
Q3 25
$119.2M
$137.1M
Q2 25
$103.2M
$108.4M
Q1 25
$96.8M
$77.1M
Q4 24
$103.1M
$77.3M
Q3 24
$100.5M
$61.1M
Q2 24
$112.9M
$49.1M
Total Debt
PRLB
PRLB
RIGL
RIGL
Q1 26
Q4 25
$52.5M
Q3 25
$60.0M
Q2 25
$60.0M
Q1 25
$60.0M
Q4 24
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Stockholders' Equity
PRLB
PRLB
RIGL
RIGL
Q1 26
$683.1M
Q4 25
$673.9M
$391.5M
Q3 25
$664.7M
$117.6M
Q2 25
$664.7M
$81.9M
Q1 25
$656.8M
$18.6M
Q4 24
$670.2M
$3.3M
Q3 24
$680.0M
$-14.6M
Q2 24
$685.2M
$-29.9M
Total Assets
PRLB
PRLB
RIGL
RIGL
Q1 26
$778.6M
Q4 25
$763.4M
$513.6M
Q3 25
$756.9M
$242.5M
Q2 25
$743.3M
$206.7M
Q1 25
$737.5M
$176.0M
Q4 24
$743.5M
$164.0M
Q3 24
$753.8M
$139.4M
Q2 24
$758.2M
$128.4M
Debt / Equity
PRLB
PRLB
RIGL
RIGL
Q1 26
Q4 25
0.13×
Q3 25
0.51×
Q2 25
0.73×
Q1 25
3.23×
Q4 24
18.25×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRLB
PRLB
RIGL
RIGL
Operating Cash FlowLast quarter
$17.5M
$22.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
2.16×
0.08×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRLB
PRLB
RIGL
RIGL
Q1 26
$17.5M
Q4 25
$16.5M
$22.0M
Q3 25
$29.1M
$24.0M
Q2 25
$10.6M
$30.5M
Q1 25
$18.4M
$-893.0K
Q4 24
$17.3M
$14.5M
Q3 24
$24.8M
$21.7M
Q2 24
$14.4M
$302.0K
Free Cash Flow
PRLB
PRLB
RIGL
RIGL
Q1 26
Q4 25
$8.4M
Q3 25
$25.0M
Q2 25
$9.1M
Q1 25
$17.1M
Q4 24
$16.5M
Q3 24
$23.2M
Q2 24
$10.2M
FCF Margin
PRLB
PRLB
RIGL
RIGL
Q1 26
Q4 25
6.2%
Q3 25
18.5%
Q2 25
6.7%
Q1 25
13.6%
Q4 24
13.5%
Q3 24
18.5%
Q2 24
8.2%
Capex Intensity
PRLB
PRLB
RIGL
RIGL
Q1 26
Q4 25
5.9%
Q3 25
3.0%
Q2 25
1.1%
Q1 25
1.0%
Q4 24
0.7%
Q3 24
1.2%
Q2 24
3.3%
Cash Conversion
PRLB
PRLB
RIGL
RIGL
Q1 26
2.16×
Q4 25
0.08×
Q3 25
4.03×
0.86×
Q2 25
2.39×
0.51×
Q1 25
5.11×
-0.08×
Q4 24
1.01×
Q3 24
3.44×
1.75×
Q2 24
3.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRLB
PRLB

CNC Machining$63.2M45%
Injection Molding$51.1M37%
3D Printing$20.5M15%
Sheet Metal$4.4M3%
Other Revenue$207.0K0%

RIGL
RIGL

Segment breakdown not available.

Related Comparisons